Capivasertib tablets (capivasertib) official instructions complete version

Capivasertib (Capivasertib) is an oral selective AKT inhibitor, used to treat tumors that target abnormal activation of the PI3K/AKT/mTOR signaling pathway. AKTThe AKT pathway plays an important role in a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, etc. By regulating cell proliferation, apoptosis and metabolism, abnormal activation can lead to tumor growth and drug resistance. Capisetinib can exert anti-tumor effects by competitively inhibiting AKT kinase activity, blocking downstream signaling, inhibiting cancer cell proliferation and promoting apoptosis.

The oral dosage form of this product is tablets, and the common specifications are 80mg/ tablets or 160mg/ tablets. The recommended starting dose is usually 400mg each time, twice a day, in a cycle of 4 days to 7 days. The specific dose and cycle need to be adjusted based on the patient's individual situation and tolerance. When taking the medicine, it is recommended to swallow the tablet whole and do not chew or crush it. It can be taken with a meal or on an empty stomach. However, if gastrointestinal discomfort occurs, it can be taken with a meal to reduce adverse reactions. Patients should strictly abide by the doctor's instructions while taking the medication and are not allowed to change the dosage or stop the medication on their own.

Clinical trials have shown that capicitinib shows good anti-tumor activity in HR+, HER2- breast cancer and PIK3CA/AKT mutation-positive patients. Single drug or combined with endocrine therapy can significantly prolong progression-free survival (PFS), and some patients can achieve partial response or shrinkage of lesions. Common adverse reactions include diarrhea, rash, elevated blood sugar, fatigue, nausea, and high blood pressure. They are usually mild to moderate and can be alleviated through symptomatic treatment or dose adjustment. Serious adverse reactions require immediate discontinuation of medication and medical treatment.

Before using capicitinib, patients need to undergo basic tests such as blood sugar, liver and kidney function, and routine blood tests. Diabetic patients should closely monitor blood sugar changes during medication and adjust the blood sugar-lowering plan if necessary. Patients with hepatic or renal insufficiency need to adjust the dose under the guidance of a doctor. When using other drugs in combination, attention should be paid to potential drug interactions. For example, coadministration with strong CYP3A inhibitors may increase blood drug concentrations and increase the risk of adverse reactions.

In terms of safety management, blood routine, liver and kidney function, blood pressure and blood sugar should be reviewed regularly during medication. Treatment should be suspended or reduced in the event of severe rash, abnormal liver function or severe diarrhea. It is prohibited for pregnant women and lactating women. Patients during childbearing period must take effective contraceptive measures. Children and elderly patients should use it with caution based on their individual conditions. Overall, capicitinib, as a AKT pathway-targeting drug, provides a new treatment option for patients with tumors related to PI3K/AKT/mTOR pathway abnormalities, but it must be used strictly in accordance with medical instructions and adverse reactions should be monitored.

Reference:https://reference.medscape.com/